Rituximab biosimilar launched in UK

Truxima (rituximab) is the first available biosimilar version of the B-cell-targeting monoclonal antibody rituximab.

Truxima is approved for the same indications as MabThera, the originator brand of rituximab: follicular lymphoma, diffuse large B-cell lymphoma, chronic lymphocytic leukaemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis.

Rituximab binds to CD20, a transmembrane antigen expressed on pre-B and mature B lymphocytes. Binding leads to death of B-cells via cell lysis and apoptosis.

Clinical studies in patients with rheumatoid arthritis and advanced-stage follicular lymphoma have demonstrated that Truxima is comparable to MabThera in terms of safety, immunogenicity and pharmacokinetics. Similar efficacy to MabThera has also been demonstrated in rheumatoid arthritis.

Biosimilar medicines should be prescribed by brand, according to MHRA advice.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

NICE recommends SGLT2 inhibitors for chronic kidney disease

NICE recommends SGLT2 inhibitors for chronic kidney disease

Updated NICE guidance on type II diabetes recommends...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Avoid routinely offering antidepressants for 'less severe' depression, says NICE in draft guidance
Products coming soon - live tracker

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...